The eCOO® Advantage

Conventional tissue processing techniques rely heavily on chemical and biological agents. These agents affect the inherent structural and mechanical properties of the grafts2,3,4.

eCOO® Technology provides a mild and efficient platform to clean and sterilise tissue with limited use of chemicals1. Research has shown that the use of scCO2 minimally affects the structural integrity of tissue grafts when compared to conventional processing techniques5. scCO2 treatment also removes medullary tissues responsible for adverse immune response8. In addition to the scCO2 treatment step, the eCOO® Clean process includes a viral inactivation step*. The combination of these two techniques has been shown to achieve a 12 fold reduction in the microbial load in the processed grafts**. The successful removal of cellular and medullary materials, and inactivation of viruses is the most crucial step in ensuring cleaner grafts for better patient outcomes.

Once cleaned of the cell and lipid debris, the non-sterile acellular tissues can also be sterilised using the eCOO® Ster process of the technology platform. The resulting sterile tissue can either be freeze-dried or fresh frozen. Alternatively, the non-sterile acellular tissue material can be first freeze-dried before terminal sterilisation with irradiation technologies.

The eCOO® Plus handle of the platform shows great promise with regards to the impregnation of grafts with compounds such as antibiotics. The ability of scCO2 to deeply penetrate the graft’s microstructure offers an excellent vehicle for depositing several different compounds within the graft. Our research goals are aimed at developing grafts capable of controlled release of the impregnated compounds.


For more information, please refer to the reference list on the back page of our brochure (download).


Using supercritical CO2 to produce superior quality allografts improves patient care by delivering a safer, more efficient product

Dr. H. Winkler, Managing Director of BioTiss GmBH.